Datapoint: J&J’s Ponvory to Enter MS Market

The FDA last week approved Johnson & Johnson’s Janssen unit’s Ponvory for the treatment of relapsing forms of multiple sclerosis (MS). The SIP modulator will face off against Novartis stalwarts Gilenya and Mayzent. Another recent entry into the MS space is Bristol Myers Squibb’s Zeposia, which won FDA approval in March 2020. For the treatment of MS under the pharmacy benefit, Zeposia currently holds preferred formulary placement for 5% of covered lives, growing to 22% with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 3/17/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 7

Datapoint: Gilead Scores Broader Breast Cancer Nod for Trodelvy

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 6

Datapoint: New Mexico Cancels Medicaid RFP

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 2

Datapoint: Blue Shield of California Launches Virtual-First Plan

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today